Home/Matinas Biopharma/Edward Neugeboren
EN

Edward Neugeboren

Independent Member, Board of Directors; Chair of Compensation Committee

Matinas Biopharma

Matinas Biopharma Pipeline

DrugIndicationPhase
MAT2203Invasive Candidiasis and AspergillosisPhase 2
LNC Platform (siRNA/ASO delivery)Inflammation (implied from research)Preclinical